VERU INC. Research and Development Expense
VERU INC. (VERU) reported Research and Development Expense of $4.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- VERU INC. research and development expense for the quarter ending 2026-06-30 was $4.35M, a 44.10% increase year-over-year.
- VERU INC. research and development expense for the quarter ending 2026-03-31 was $3.15M, a 20.00% decline year-over-year.
- VERU INC. research and development expense for the quarter ending 2025-12-31 was $1.34M, a 76.49% decline year-over-year.
- VERU INC. research and development expense for the quarter ending 2025-09-30 was $2.92M, a 11.35% decline year-over-year.
- VERU INC. research and development expense for fiscal 2025 was $15.59M, a 21.95% increase from fiscal 2024.
- VERU INC. research and development expense for fiscal 2024 was $12.78M, a 75.04% decline from fiscal 2023.
- VERU INC. research and development expense for fiscal 2023 was $51.20M, a 27.79% decline from fiscal 2022.
- VERU INC. research and development expense for fiscal 2022 was $70.91M, a 116.89% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.35M 10-Q · filed 2026-08-10 | $7.50M derived: sum of 2 quarters · filed 2026-08-10 | $8.84M 10-Q · filed 2026-08-10 | $11.76M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $3.15M 10-Q · filed 2026-05-13 | $4.49M 10-Q · filed 2026-05-13 | $7.41M derived: sum of 3 quarters · filed 2026-05-13 | $10.43M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $1.34M 10-Q · filed 2026-02-11 | $4.26M derived: sum of 2 quarters · filed 2026-02-11 | $7.28M derived: sum of 3 quarters · filed 2026-08-10 | $11.22M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-09-30 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $5.94M derived: sum of 2 quarters · filed 2026-08-10 | $9.87M derived: sum of 3 quarters · filed 2026-08-10 | $15.59M 10-K · filed 2025-12-17 | ||||
| 2025-06-30 | $3.02M 10-Q · filed 2026-08-10 | $6.95M derived: sum of 2 quarters · filed 2026-08-10 | $12.67M 10-Q · filed 2026-08-10 | $15.96M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $3.93M 10-Q · filed 2026-05-13 | $9.65M 10-Q · filed 2026-05-13 | $12.94M derived: sum of 3 quarters · filed 2026-05-13 | $17.79M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $5.72M 10-Q · filed 2026-02-11 | $9.01M derived: sum of 2 quarters · filed 2026-02-11 | $13.86M derived: sum of 3 quarters · filed 2026-02-11 | $16.84M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-09-30 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $8.14M derived: sum of 2 quarters · filed 2025-12-17 | $11.12M derived: sum of 3 quarters · filed 2025-12-17 | $12.78M 10-K · filed 2025-12-17 | $12.81M 10-K · filed 2024-12-16 | |||
| 2024-06-30 | $4.85M 10-Q · filed 2025-08-12 | $4.88M 10-Q · filed 2024-08-08 | $7.83M derived: sum of 2 quarters · filed 2025-08-12 | $9.49M 10-Q · filed 2025-08-12 | $9.52M 10-Q · filed 2024-08-08 | $13.43M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $2.99M 10-Q · filed 2025-05-08 | $2.99M 10-Q · filed 2024-05-08 | $4.64M 10-Q · filed 2025-05-08 | $4.64M 10-Q · filed 2024-05-08 | $8.59M derived: sum of 3 quarters · filed 2025-05-08 | $17.37M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $1.66M 10-Q · filed 2025-02-13 | $1.65M 10-Q · filed 2024-04-01 | $5.60M derived: sum of 2 quarters · filed 2025-02-13 | $14.39M derived: sum of 3 quarters · filed 2025-02-13 | $32.25M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-09-30 | $3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $12.73M derived: sum of 2 quarters · filed 2024-12-16 | $30.59M derived: sum of 3 quarters · filed 2024-12-16 | $51.20M 10-K · filed 2024-12-16 | $51.14M 10-K · filed 2023-12-08 | |||
| 2023-06-30 | $8.79M 10-Q · filed 2024-08-08 | $2.93M 10-Q · filed 2023-08-10 | $26.65M derived: sum of 2 quarters · filed 2024-08-08 | $47.26M 10-Q · filed 2024-08-08 | $44.53M 10-Q · filed 2023-08-10 | $74.41M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $17.86M 10-Q · filed 2024-05-08 | $22.86M 10-Q · filed 2023-05-11 | $38.47M 10-Q · filed 2024-05-08 | $41.61M 10-Q · filed 2023-05-11 | $65.63M derived: sum of 3 quarters · filed 2024-05-08 | $83.76M derived: sum of 4 quarters · filed 2024-05-08 | ||
| 2022-12-31 | $20.61M 10-K/A · filed 2024-04-01 | $18.74M 10-Q · filed 2023-02-09 | $47.77M derived: sum of 2 quarters · filed 2024-04-01 | $65.90M derived: sum of 3 quarters · filed 2024-04-01 | $81.44M derived: sum of 4 quarters · filed 2024-04-01 | |||
| 2022-09-30 | $27.16M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | $45.29M derived: sum of 2 quarters · filed 2024-04-01 | $60.83M derived: sum of 3 quarters · filed 2024-04-01 | $70.91M 10-K/A · filed 2024-04-01 | $70.65M 10-K · filed 2022-12-05 | |||
| 2022-06-30 | $18.13M 10-Q/A · filed 2023-11-15 | $33.67M derived: sum of 2 quarters · filed 2023-11-15 | $43.76M 10-Q/A · filed 2023-11-15 | $52.01M derived: sum of 4 quarters · filed 2023-11-15 | ||||
| 2022-03-31 | $15.54M 10-Q · filed 2023-05-11 | $25.62M 10-Q · filed 2023-05-11 | $33.88M derived: sum of 3 quarters · filed 2023-05-11 | $45.07M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $10.08M 10-Q · filed 2023-02-09 | $18.34M derived: sum of 2 quarters · filed 2023-02-09 | $29.52M derived: sum of 3 quarters · filed 2023-02-09 | $37.10M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-09-30 | $8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $19.44M derived: sum of 2 quarters · filed 2022-12-05 | $27.02M derived: sum of 3 quarters · filed 2022-12-05 | $32.69M 10-K · filed 2022-12-05 | ||||
| 2021-06-30 | $11.19M 10-Q · filed 2022-08-11 | $18.76M derived: sum of 2 quarters · filed 2022-08-11 | $24.44M 10-Q · filed 2022-08-11 | $27.71M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $7.57M 10-Q · filed 2022-05-12 | $13.25M 10-Q · filed 2022-05-12 | $16.52M derived: sum of 3 quarters · filed 2022-05-12 | $20.96M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $5.68M 10-Q · filed 2022-02-09 | $8.95M derived: sum of 2 quarters · filed 2022-02-09 | $13.38M derived: sum of 3 quarters · filed 2022-02-09 | $17.31M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-09-30 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $7.70M derived: sum of 2 quarters · filed 2021-12-02 | $11.64M derived: sum of 3 quarters · filed 2021-12-02 | $16.94M 10-K · filed 2021-12-02 | ||||
| 2020-06-30 | $4.44M 10-Q · filed 2021-08-12 | $8.37M derived: sum of 2 quarters · filed 2021-08-12 | $13.67M 10-Q · filed 2021-08-12 | $17.27M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $3.93M 10-Q · filed 2021-05-12 | $9.23M 10-Q · filed 2021-05-12 | $12.84M derived: sum of 3 quarters · filed 2021-05-12 | $17.70M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | $5.30M 10-Q · filed 2021-02-10 | $8.91M derived: sum of 2 quarters · filed 2021-02-10 | $13.77M derived: sum of 3 quarters · filed 2021-02-10 | $16.68M derived: sum of 4 quarters · filed 2021-02-10 | ||||
| 2019-09-30 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $8.47M derived: sum of 2 quarters · filed 2020-12-10 | $11.38M derived: sum of 3 quarters · filed 2020-12-10 | $13.74M 10-K · filed 2020-12-10 | ||||
| 2019-06-30 | $4.87M 10-Q · filed 2020-08-13 | $7.78M derived: sum of 2 quarters · filed 2020-08-13 | $10.14M 10-Q · filed 2020-08-13 | $13.17M derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | $2.91M 10-Q · filed 2020-05-13 | $5.27M 10-Q · filed 2020-05-13 | $8.30M derived: sum of 3 quarters · filed 2020-05-13 | $12.09M derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | $2.36M 10-Q · filed 2020-02-12 | $5.39M derived: sum of 2 quarters · filed 2020-02-12 | $9.18M derived: sum of 3 quarters · filed 2020-02-12 | $11.25M derived: sum of 4 quarters · filed 2020-02-12 | ||||
| 2018-09-30 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-12 | $6.82M derived: sum of 2 quarters · filed 2019-12-12 | $8.89M derived: sum of 3 quarters · filed 2019-12-12 | $10.85M 10-K · filed 2019-12-12 | ||||
| 2018-06-30 | $3.79M 10-Q · filed 2019-08-08 | $5.86M derived: sum of 2 quarters · filed 2019-08-08 | $7.82M 10-Q · filed 2019-08-08 | $9.22M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $2.08M 10-Q · filed 2019-05-15 | $4.04M 10-Q · filed 2019-05-15 | $5.43M derived: sum of 3 quarters · filed 2019-05-15 | $5.74M derived: sum of 4 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | $1.96M 10-Q · filed 2019-02-13 | $2.04M 10-Q · filed 2018-02-14 | $3.36M derived: sum of 2 quarters · filed 2019-02-13 | $3.66M derived: sum of 3 quarters · filed 2019-02-13 | $4.87M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2017-09-30 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-13 | $1.70M derived: sum of 2 quarters · filed 2018-12-13 | $2.91M derived: sum of 3 quarters · filed 2018-12-13 | $3.08M 10-K · filed 2018-12-13 | $3.50M 10-K · filed 2018-01-02 | |||
| 2017-06-30 | $302.07K 10-Q · filed 2018-08-14 | $426.81K 10-Q · filed 2017-08-09 | $1.51M derived: sum of 2 quarters · filed 2018-08-14 | $1.68M 10-Q · filed 2018-08-14 | $2.03M 10-Q · filed 2017-08-09 | $1.68M derived: sum of 4 quarters · filed 2018-08-14 | ||
| 2017-03-31 | $1.21M 10-Q · filed 2018-05-11 | $1.44M 10-Q · filed 2017-05-10 | $1.37M 10-Q · filed 2018-05-11 | $1.61M 10-Q · filed 2017-05-10 | $1.38M derived: sum of 3 quarters · filed 2018-05-11 | $1.40M derived: sum of 4 quarters · filed 2018-05-11 | ||
| 2016-12-31 | $171.10K 10-Q · filed 2018-02-14 | $174.35K derived: sum of 2 quarters · filed 2018-02-14 | $197.08K derived: sum of 3 quarters · filed 2018-02-14 | $232.20K derived: sum of 4 quarters · filed 2018-02-14 | ||||
| 2016-09-30 | $3.25K derived: 10-K 12 month − 10-Q 9 month · filed 2018-01-02 | $25.98K derived: sum of 2 quarters · filed 2018-01-02 | $61.10K derived: sum of 3 quarters · filed 2018-01-02 | $99.39K 10-K · filed 2018-01-02 | ||||
| 2016-06-30 | $22.72K 10-Q · filed 2017-08-09 | $57.84K derived: sum of 2 quarters · filed 2017-08-09 | $96.14K 10-Q · filed 2017-08-09 | |||||
| 2016-03-31 | $35.12K 10-Q · filed 2017-05-10 | $73.42K 10-Q · filed 2017-05-10 | ||||||
| 2015-09-30 | $219.81K 10-K · filed 2018-01-02 | |||||||
| 2014-09-30 | $5.58K 10-K · filed 2016-12-12 | |||||||
| 2013-09-30 | $4.75K 10-K · filed 2015-12-02 | |||||||
| 2012-09-30 | $5.28K 10-K · filed 2014-12-02 | |||||||
| 2011-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-03 | $2.07K derived: sum of 2 quarters · filed 2013-12-03 | $10.93K 10-K · filed 2013-12-03 | |||||
| 2011-06-30 | $2.07K 10-Q · filed 2011-08-05 | $10.93K 10-Q · filed 2011-08-05 | ||||||
| 2010-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-04 | $381.00 10-K · filed 2012-12-04 | ||||||
| 2010-06-30 | $381.00 10-Q · filed 2011-08-05 | |||||||
| 2009-09-30 | $105.92K 10-K · filed 2011-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |